Extensively Drug-resistant Tuberculosis

Miguel G. Madariaga, Umesh G. Lalloo, Susan Swindells

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Extensively drug-resistant tuberculosis (XDR-TB) is defined as Mycobacterium tuberculosis infection that is resistant to isoniazid, rifampin, any fluoroquinolone, and any injectable drug (amynoglicosides or polypetides). Although initially described in South Africa, it has emerged as a global threat, and cases have been reported from several countries, including the United States. XDR-TB has emerged mainly as a consequence of previous inadequate or poorly administered treatment, from failure of the public health infrastructure. As the diagnosis of this condition requires antibiotic susceptibility confirmation, a broad network of reference laboratories and the development of faster and more accurate tests for the identification of active cases of tuberculosis are urgently required. The treatment of XDR-TB is challenging and requires the use of multiple second-line drugs and, potentially, surgery. Infection control measures do not differ from those used for susceptible cases but may require more stringent application.

Original languageEnglish (US)
Pages (from-to)835-844
Number of pages10
JournalAmerican Journal of Medicine
Volume121
Issue number10
DOIs
StatePublished - Oct 1 2008

Fingerprint

Extensively Drug-Resistant Tuberculosis
Mycobacterium Infections
Fluoroquinolones
Isoniazid
Rifampin
Infection Control
South Africa
Treatment Failure
Mycobacterium tuberculosis
Pharmaceutical Preparations
Tuberculosis
Public Health
Anti-Bacterial Agents
Injections

Keywords

  • Extensively drug resistant
  • HIV
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Extensively Drug-resistant Tuberculosis. / Madariaga, Miguel G.; Lalloo, Umesh G.; Swindells, Susan.

In: American Journal of Medicine, Vol. 121, No. 10, 01.10.2008, p. 835-844.

Research output: Contribution to journalReview article

Madariaga, Miguel G. ; Lalloo, Umesh G. ; Swindells, Susan. / Extensively Drug-resistant Tuberculosis. In: American Journal of Medicine. 2008 ; Vol. 121, No. 10. pp. 835-844.
@article{5fb034ec9e2240ed937e99ca8ccaf7f6,
title = "Extensively Drug-resistant Tuberculosis",
abstract = "Extensively drug-resistant tuberculosis (XDR-TB) is defined as Mycobacterium tuberculosis infection that is resistant to isoniazid, rifampin, any fluoroquinolone, and any injectable drug (amynoglicosides or polypetides). Although initially described in South Africa, it has emerged as a global threat, and cases have been reported from several countries, including the United States. XDR-TB has emerged mainly as a consequence of previous inadequate or poorly administered treatment, from failure of the public health infrastructure. As the diagnosis of this condition requires antibiotic susceptibility confirmation, a broad network of reference laboratories and the development of faster and more accurate tests for the identification of active cases of tuberculosis are urgently required. The treatment of XDR-TB is challenging and requires the use of multiple second-line drugs and, potentially, surgery. Infection control measures do not differ from those used for susceptible cases but may require more stringent application.",
keywords = "Extensively drug resistant, HIV, Tuberculosis",
author = "Madariaga, {Miguel G.} and Lalloo, {Umesh G.} and Susan Swindells",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.amjmed.2008.04.015",
language = "English (US)",
volume = "121",
pages = "835--844",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Extensively Drug-resistant Tuberculosis

AU - Madariaga, Miguel G.

AU - Lalloo, Umesh G.

AU - Swindells, Susan

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Extensively drug-resistant tuberculosis (XDR-TB) is defined as Mycobacterium tuberculosis infection that is resistant to isoniazid, rifampin, any fluoroquinolone, and any injectable drug (amynoglicosides or polypetides). Although initially described in South Africa, it has emerged as a global threat, and cases have been reported from several countries, including the United States. XDR-TB has emerged mainly as a consequence of previous inadequate or poorly administered treatment, from failure of the public health infrastructure. As the diagnosis of this condition requires antibiotic susceptibility confirmation, a broad network of reference laboratories and the development of faster and more accurate tests for the identification of active cases of tuberculosis are urgently required. The treatment of XDR-TB is challenging and requires the use of multiple second-line drugs and, potentially, surgery. Infection control measures do not differ from those used for susceptible cases but may require more stringent application.

AB - Extensively drug-resistant tuberculosis (XDR-TB) is defined as Mycobacterium tuberculosis infection that is resistant to isoniazid, rifampin, any fluoroquinolone, and any injectable drug (amynoglicosides or polypetides). Although initially described in South Africa, it has emerged as a global threat, and cases have been reported from several countries, including the United States. XDR-TB has emerged mainly as a consequence of previous inadequate or poorly administered treatment, from failure of the public health infrastructure. As the diagnosis of this condition requires antibiotic susceptibility confirmation, a broad network of reference laboratories and the development of faster and more accurate tests for the identification of active cases of tuberculosis are urgently required. The treatment of XDR-TB is challenging and requires the use of multiple second-line drugs and, potentially, surgery. Infection control measures do not differ from those used for susceptible cases but may require more stringent application.

KW - Extensively drug resistant

KW - HIV

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=52949137826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949137826&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2008.04.015

DO - 10.1016/j.amjmed.2008.04.015

M3 - Review article

C2 - 18823850

AN - SCOPUS:52949137826

VL - 121

SP - 835

EP - 844

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 10

ER -